Today: 29 April 2026
Browse Category

TSX:4543 26 August 2025

Billion-Dollar Pharma Deals, Biotech Breakthroughs & Global Health Alerts – Biotech & Health News Roundup (Aug 25–26, 2025)

Billion-Dollar Pharma Deals, Biotech Breakthroughs & Global Health Alerts – Biotech & Health News Roundup (Aug 25–26, 2025)

AbbVie agreed to acquire Gilgamesh Pharmaceuticals’ experimental psychedelic depression drug for up to $1.2 billion, planning to advance it to Phase 3 trials. Japan’s Terumo will buy UK-based OrganOx for $1.5 billion, gaining organ preservation technology. LB Pharma filed for a $100 million IPO, the first biotech IPO in six months. Arnatar Therapeutics raised $52 million to develop RNA therapy for Alagille syndrome.
26 August 2025
··

Stock Market Today

  • Chevron (CVX) Appears Undervalued After 10.8% Drop: DCF Analysis Shows 47.5% Discount
    April 28, 2026, 10:57 PM EDT. Chevron's shares closed at $188.36, down 10.8% over the past month but up 41.3% over the last year. A Discounted Cash Flow (DCF) analysis estimates Chevron's intrinsic value at $358.56 per share, suggesting the stock trades at a 47.5% discount, indicating potential undervaluation. The DCF model factors in free cash flow projections through 2035, reflecting a strong future cash generation outlook. Chevron's price-to-earnings (P/E) ratio stands at 30.5x, elevated relative to the Oil and Gas sector average, reflecting market expectations for earnings growth and risk. Investors continue to weigh commodity prices, capital spending, and shareholder return policies amid fluctuating energy market conditions.

Latest article

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

29 April 2026
AST SpaceMobile will hold its first-quarter update call on May 11 after winning FCC approval to deploy a 248-satellite constellation for direct-to-device service. Shares fell 6.8% Tuesday, following the loss of its BlueBird 7 satellite in a failed launch. The company expects insurance to cover the loss and is targeting 45 satellites in orbit by end-2026. Investors are watching launch progress and commercial service timing.
OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

29 April 2026
Oracle shares fell 4% and CoreWeave dropped 5.9% Tuesday after a Wall Street Journal report said OpenAI missed recent revenue and user targets. Nvidia, AMD, and Arm Holdings also declined, with the iShares Semiconductor ETF down 3.7%. OpenAI denied internal divisions and said its AI coding product Codex reached 4 million users. Oracle’s credit default swaps hit a two-week high amid concern over its $300 billion cloud deal with OpenAI.
Go toTop